TTrialPathMatch Me to Trials
← Back to trials
RecruitingSolid Tumor

A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors

Eligible age

18+ yrs

Accepts

All genders

Locations

5 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This is a Phase Ia/Ib open-label, dose-escalation study to evaluate the safety and pharmacokinetics of ROSE12 as a single agent and in combination with other anti-tumor agents in patients with locally advanced or metastatic solid tumors. The study will consist of three parts: a dose-escalation part, a biopsy part (the part to evaluate biomarkers), and an expansion part.

Sponsor: Chugai Pharmaceutical

You may not qualify if…

  • ✕ Clinically significant cardiovascular or liver disease
  • ✕ Treatment with investigational therapy and anti-cancer therapy within 28 days prior to initiation of study drug
  • ✕ Any history of an immune-mediated Grade 4 adverse event attributed to prior cancer immunotherapy (other than asymptomatic elevation of serum amylase or lipase).
  • ✕ All imAEs from prior cancer immunotherapy (other than endocrinopathy managed with replacement therapy, stable vitiligo or stable alopecia) that have not resolved completely to baseline.
  • ✕ Adverse events from prior anti-cancer therapy that have not resolved to Grade ≤ 1 except for alopecia, vitiligo, or endocrinopathy managed with replacement therapy
  • ✕ Primary central nervous system (CNS) malignancy, untreated CNS metastases requiring any anti-tumor treatment, or active CNS metastases
  • ✕ Uncontrolled tumor-related pain
  • ✕ Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures

Where it's recruiting

Pennsylvania

Philadelphia

Rhode Island

Providence

Tennessee

Nashville

Texas

Houston

Virginia

Fairfax

Source: ClinicalTrials.gov · NCT05907980 · last updated 2026-07-28